FDA approves AQUI-S E10% for wild freshwater fish sedation

The FDA has approved AQUI-S E10% (eugenol immersion solution) for sedating wild freshwater finfish to a handleable condition, creating a new legal option for field resource management work in the U.S. The approval, dated August 25, 2026, is limited to field use in wild freshwater fish populations, not aquaculture or hatchery settings, and is intended for activities such as spawning, tagging, weighing, measuring, and sampling. FDA said treated fish can be released directly back into the water after recovery. (fda.gov)

This approval closes a long-running regulatory gap. Fisheries professionals have spent years seeking an immediate-release sedative that could be used legally in the field, especially because commonly discussed alternatives came with important restrictions. FDA has previously emphasized that clove oil is not approved for any fish use, and that MS-222 cannot be used for fish that will be immediately returned to the wild. Earlier FDA and American Fisheries Society materials also noted that AQUI-S 20E, the development name for the same 10% eugenol product, had been available only through the U.S. Fish & Wildlife Service’s investigational new animal drug, or INAD, pathway. (fda.gov)

According to FDA’s approval announcement and Freedom of Information summary, the product is an over-the-counter immersion sedative supplied in 1-liter and 4-liter containers, with labeled dosage ranges of 25 to 40 mg/L for freshwater salmonids and 40 to 100 mg/L for freshwater non-salmonids. The approval is broad in species scope: supporting field studies included rainbow trout, brown trout, cutthroat trout, lake trout, walleye, yellow perch, Nile tilapia, blue catfish, hybrid striped bass, channel catfish, common carp, and fathead minnows. Across those studies, mean sedation times ranged from 1.3 to 3.2 minutes in salmonids and 0.9 to 3.1 minutes in non-salmonids, while mean recovery times ranged from 3.6 to 10.8 minutes and 1.9 to 14.4 minutes, respectively. (animaldrugsatfda.fda.gov)

FDA’s safety review also addressed both fish welfare and food safety. Margin-of-safety studies in rainbow trout, yellow perch, and channel catfish found adequate safety margins at intended-use concentrations, with transient headshaking among some exposed fish but no significant treatment-related lesions reported. On the human food side, FDA concluded that residues in edible tissues would not pose a public health concern, established an acute reference dose for eugenol, and did not assign a tolerance because total residues were substantially below the safe concentration threshold. The agency’s summary also notes that people handling the product should use protective equipment, including gloves and eyewear, and avoid skin and eye contact. (animaldrugsatfda.fda.gov)

Direct third-party reaction to this week’s approval appears limited so far, but the broader professional context suggests the move will be welcomed by fisheries and aquatic animal health programs. A 2022 veterinary review on fish sedation and anesthesia underscored that sedation is often necessary for examinations, diagnostics, transport, and field procedures, while also noting that regulations and withdrawal times can sharply limit practical options in food species. That helps explain why an approved, immediate-release field sedative has been a persistent need in fisheries management. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinarians and fish health professionals, this is less about companion animal practice and more about the infrastructure of aquatic medicine, conservation, and public resource management. A legally approved sedative for wild freshwater finfish can make field handling more consistent, reduce stress during routine management procedures, and simplify compliance for agencies and collaborating clinicians. It also gives veterinary professionals a clearer regulatory framework when advising wildlife programs, hatchery-adjacent operations, or academic teams that work with fish in the field. (fda.gov)

The approval may also sharpen the boundary between approved eugenol products and nonapproved clove-oil use. FDA updated Guidance for Industry #150 in August 2026 to list AQUI-S E10% as an approved drug while maintaining its broader cautionary stance on clove oil and its components. In practical terms, that means professionals should not assume that chemically related products are interchangeable from a regulatory or safety standpoint. (fda.gov)

What to watch: Next, watch for how quickly state and federal fisheries programs integrate AQUI-S E10% into standard operating procedures, whether post-approval field experience supports wider species adoption, and whether the sponsor pursues future label expansions into additional settings, including saltwater or non-field applications. That last point is an inference based on the product’s long development history and prior investigational work, not a stated FDA plan. (animaldrugsatfda.fda.gov)